QYUNS-B (02509.HK): TL1A/IL-17 Bispecific Licensed to Caldera
On 5 November 2026, QYUNS-B licensed a preclinical TL1A/IL-17 bispecific to Caldera for USD30 million upfront and up to USD750 million in sales milestones.
Key Highlights:
- The licence covers a preclinical bispecific antibody programme targeting TL1A and IL-17.
- The Group receives USD30 million upfront, up to USD750 million in milestones and tiered royalties on net sales.
NewTimeSpace News: On 5 November 2026, Qyuns Therapeutics Co., Ltd. (Stock Code: 2509) announced a licence agreement with Caldera Therapeutics, Inc. for a preclinical bispecific antibody programme targeting TL1A and IL-17.
The announcement shows that Caldera received an exclusive, royalty-bearing, transferable and sublicensable right to research, develop, register, manufacture and commercialise candidate products worldwide. The Group will receive USD30 million upfront, non-refundable and non-creditable, up to USD750 million upon clinical, regulatory and commercial milestones, and tiered royalties on net sales. The programme comprises preclinical bispecific antibodies designed to inhibit TL1A and IL-17.
